New anthrax vaccine moves forward in human trials
NCT ID NCT05997264
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an anthrax vaccine called AV7909 in 220 healthy adults aged 18 to 65. The goal is to see how safe it is and how well it triggers the immune system, using two different dosing schedules and booster shots at 6 and 12 months. Participants will be monitored for side effects and antibody levels.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTHRAX are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Accellacare Knoxville
Jefferson City, Tennessee, 37760, United States
-
Accellacare Knoxville
Knoxville, Tennessee, 37912, United States
-
Accellacare Knoxville
Knoxville, Tennessee, 37938, United States
-
Accellacare of Hickory
Hickory, North Carolina, 28601, United States
-
Accellacare of Piedmont
Statesville, North Carolina, 28625, United States
-
Accellacare of Salisbury
Salisbury, North Carolina, 28144, United States
-
Accellacare of Winston-Salem
Winston-Salem, North Carolina, 27103, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.